Jacky Créquit

761 total citations
18 papers, 368 citations indexed

About

Jacky Créquit is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jacky Créquit has authored 18 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 3 papers in Surgery. Recurrent topics in Jacky Créquit's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jacky Créquit is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jacky Créquit collaborates with scholars based in France, United States and Luxembourg. Jacky Créquit's co-authors include C. Chouaïd, A. Vergnenègre, L. Falchero, Paul Soler, Fabrice Barlési, Bruno Crestani, P. Fournel, M. Kambouchner, Dominique Valeyre and J P Battesti and has published in prestigious journals such as Journal of Clinical Oncology, European Respiratory Journal and BMC Cancer.

In The Last Decade

Jacky Créquit

17 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacky Créquit France	9	306	229	47	39	37	18	368
M. Guirado Spain	9	254 0.8×	202 0.9×	27 0.6×	54 1.4×	30 0.8×	24	361
Fernando Barata Portugal	11	294 1.0×	262 1.1×	25 0.5×	72 1.8×	16 0.4×	61	438
Melissa A.L. Vyfhuis United States	10	201 0.7×	182 0.8×	35 0.7×	28 0.7×	60 1.6×	30	390
Henrique Queiroga Portugal	11	170 0.6×	122 0.5×	25 0.5×	28 0.7×	26 0.7×	37	253
Francesco Cortiula Italy	10	170 0.6×	202 0.9×	35 0.7×	51 1.3×	26 0.7×	38	324
Jeffrey T. Yorio United States	8	136 0.4×	193 0.8×	70 1.5×	30 0.8×	15 0.4×	22	323
Athanasios Karampeazis Greece	10	221 0.7×	245 1.1×	25 0.5×	23 0.6×	10 0.3×	26	317
Arnold Cyjon Israel	8	327 1.1×	296 1.3×	29 0.6×	65 1.7×	17 0.5×	18	435
Sameh Daher Israel	10	155 0.5×	294 1.3×	40 0.9×	37 0.9×	19 0.5×	15	374
J.W.G. van Putten Netherlands	9	229 0.7×	225 1.0×	29 0.6×	67 1.7×	18 0.5×	11	402

Countries citing papers authored by Jacky Créquit

Since Specialization

Citations

This map shows the geographic impact of Jacky Créquit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacky Créquit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacky Créquit more than expected).

Fields of papers citing papers by Jacky Créquit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacky Créquit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacky Créquit. The network helps show where Jacky Créquit may publish in the future.

Co-authorship network of co-authors of Jacky Créquit

This figure shows the co-authorship network connecting the top 25 collaborators of Jacky Créquit. A scholar is included among the top collaborators of Jacky Créquit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacky Créquit. Jacky Créquit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Baize, Nathalie, I. Monnet, Laurent Greillier, et al.. (2019). OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 5 indexed citations

Grivaux, M, et al.. (2016). Early mortality in lung cancer: French prospective multicentre observational study. BMC Pulmonary Medicine. 16(1). 45–45. 15 indexed citations

Barlési, Fabrice, C. Chouaïd, Jacky Créquit, et al.. (2015). A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Interactive Cardiovascular and Thoracic Surgery. 20(6). 783–790. 9 indexed citations

Lerouge, D., Alain Rivière, Éric Dansin, et al.. (2014). A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer. 14(1). 231–231. 16 indexed citations

Borget, Isabelle, M. Pérol, David Pérol, et al.. (2014). Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. BMC Cancer. 14(1). 953–953. 8 indexed citations

Caer, H. Le, C. Chouaïd, R. Corre, et al.. (2014). Impact of a comprehensive geriatric assessment on management strategies in elderly patients with advanced no small cell lung cancer (NSCLC): A polled analysis of two phase 2 prospective study of the GFPC group. Journal of Geriatric Oncology. 5. S17–S18. 3 indexed citations

Debieuvre, D., Chrystèle Locher, Jacky Créquit, et al.. (2013). Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts. European Respiratory Journal. 42(Suppl 57). 1819–1819.

Bylicki, Olivier, Céline Ferlay, C. Chouaïd, et al.. (2013). Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study. Journal of Thoracic Oncology. 8(7). 906–914. 5 indexed citations

Pérol, M., C. Chouaïd, David Pérol, et al.. (2012). Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(28). 3516–3524. 166 indexed citations

10.

Greillier, Laurent, R. Corre, Jacky Créquit, et al.. (2012). A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer. 77(1). 97–103. 18 indexed citations

11.

Bylicki, Olivier, Céline Ferlay, C. Chouaïd, et al.. (2012). Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.. Journal of Clinical Oncology. 30(15_suppl). 7574–7574. 1 indexed citations

12.

Chouaïd, C., H. Le Caer, R. Corre, et al.. (2011). PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505). Value in Health. 14(7). A448–A448. 1 indexed citations

13.

Vergnenègre, A., R. Corre, H. Bérard, et al.. (2010). Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study. Journal of Thoracic Oncology. 6(1). 161–168. 27 indexed citations

14.

Vergnenègre, A., H. Bérard, D. Paillotin, et al.. (2009). PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE) 05–06 STUDY. Value in Health. 12(7). A281–A281. 1 indexed citations

15.

Barlési, Fabrice, C. Chouaïd, Jacky Créquit, et al.. (2009). Randomized trial of adjuvant chemotherapy (Cx) with cisplatin plus gemcitabine (CG) versus cisplatin plus docetaxel (CD) in patients (pts) with completely resected non-small cell lung cancer (NSCLC) with quality of life (QoL) as the primary objective. Journal of Clinical Oncology. 27(15_suppl). 7532–7532. 1 indexed citations

16.

Barlési, Fabrice, G. Robinet, P. Fournel, et al.. (2007). An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. Lung Cancer. 57(1). 72–78. 13 indexed citations

17.

Robinet, G., L. Falchero, M. Pérol, et al.. (2005). O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer. Lung Cancer. 49. S33–S33. 3 indexed citations

18.

Crestani, Bruno, M. Kambouchner, Paul Soler, et al.. (1995). Migratory bronchiolitis obliterans organizing pneumonia after unilateral radiation therapy for breast carcinoma. European Respiratory Journal. 8(2). 318–321. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact